NCT01944293View on ClinicalTrials.gov

Ketamine for Suicidality in Bipolar Depression

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

October 31, 2018

Conditions
Bipolar DisorderMajor Depressive EpisodeSuicidal Ideation
Interventions
DRUG

Ketamine

Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes

DRUG

Midazolam

Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes

Trial Locations (1)

10032

Columbia University/New York State Psychiatric Institute, New York

Sponsors
All Listed Sponsors
collaborator

Brain & Behavior Research Foundation

OTHER

lead

New York State Psychiatric Institute

OTHER